End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1,629 MXN | +1.22% |
|
-.--% | -.--% |
03/07 | Bain, Cinven Said to Weigh Joint Bid for Sanofi's Consumer Health Division | MT |
03/07 | Bain, Cinven Said to Weigh Joint Bid for Sanofi's Consumer Health Division | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-.--% | 121B | - | ||
+54.07% | 816B | C+ | ||
+38.59% | 634B | B | ||
-7.05% | 351B | C+ | ||
+15.44% | 323B | B- | ||
+5.72% | 293B | C+ | ||
+13.40% | 238B | B+ | ||
+0.61% | 222B | A+ | ||
+13.24% | 218B | B- | ||
+7.42% | 167B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- SAN Stock
- SAN1 N Stock
- Ratings Sanofi